A new era for treatment of drug-resistant tuberculosis
Authors:
- 4 October 2018
- journal article
- editorial
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 52 (4) , 1801350
Abstract
Adoption of new treatment regimens for drug-resistant TB has been slowed amid concerns regarding their efficacy and safety. Numerous studies worldwide now provide substantial evidence to support widespread implementation of these new drugs and regimens.http://ow.ly/FX8I30lpANXKeywords
Funding Information
- National Institute of Allergy and Infectious Diseases (K24AI114444, R01AI114304, R01AI138646)
This publication has 25 references indexed in Scilit:
- WHO recommendations on shorter treatment of multidrug-resistant tuberculosisThe Lancet, 2016
- Carbapenems to Treat Multidrug and Extensively Drug-Resistant Tuberculosis: A Systematic ReviewInternational Journal of Molecular Sciences, 2016
- Preferential adherence to antiretroviral therapy over tuberculosis treatment: A qualitative study of drug-resistant TB/HIV co-infected patients in South AfricaGlobal Public Health, 2014
- Linezolid for Treatment of Chronic Extensively Drug-Resistant TuberculosisNew England Journal of Medicine, 2012
- Delamanid for Multidrug-Resistant Pulmonary TuberculosisNew England Journal of Medicine, 2012
- High rate of hypothyroidism among patients treated for multidrug-resistant tuberculosis in LesothoThe International Journal of Tuberculosis and Lung Disease, 2012
- MDR Tuberculosis — Critical Steps for Prevention and ControlNew England Journal of Medicine, 2010
- Short, Highly Effective, and Inexpensive Standardized Treatment of Multidrug-resistant TuberculosisAmerican Journal of Respiratory and Critical Care Medicine, 2010
- Adverse events related to multidrug-resistant tuberculosis treatment, Latvia, 2000-2004.2010
- The Diarylquinoline TMC207 for Multidrug-Resistant TuberculosisNew England Journal of Medicine, 2009